Xinhua Biologics Completes Tens of Millions of Dollars Series A+ Financing to Advance Global Clinical Development of Innovative Vaccines and Biologics

Gelonghui August 25 | Apricot Zeal Capital announced the completion of a multi-million-dollar Series A+ financing round for Vibrant Therapeutics (Guangzhou) Co., Ltd. ("Vibrant"), led by Apricot Zeal Capital. The funds will primarily be used to advance the company’s core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.